Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE

 
• By Alaric DeArment
  
Editas announced data from the Phase I/II BRILLIANCE trial of EDIT-101 in LCA10 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies